Short Term Rating on Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX) has an average broker rating of 1.63, which is interpreted as a Buy, as rated by 15 equity analysts. Nonetheless, 9 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Vertex Pharmaceuticals Incorporated (VRTX) : Average target price received by Vertex Pharmaceuticals Incorporated (VRTX) is $115.67 with an expected standard deviation of $22.22. The most aggressive target on the stock is $155, whereas the most downbeat target is $75. 12 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy.


Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): The stock opened at $91.10 on Tuesday but the bulls could not build on the opening and the stock topped out at $91.45 for the day. The stock traded down to $89.14 during the day, due to lack of any buying support eventually closed down at $89.63 with a loss of -0.52% for the day. The stock had closed at $90.10 on the previous day. The total traded volume was 1,548,387 shares.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.